Thank you!

Your quote has been successfully submitted!

For products requiring additional information, our team will contact you within 1 business day

Failed

There was an error submitting your quote. Please try again.

MSE PRO Dimiracetam, ≥98.0% Purity– MSE Supplies LLC

Overstock Sale - Select Products 10% Off on Orders of $500 or More! Promo Code:

SAVING10

Shop Now
Menu

This product has been added to the cart.

MSE PRO Dimiracetam, ≥98.0% Purity - MSE Supplies LLC

MSE PRO Dimiracetam, ≥98.0% Purity

SKU: CM1368

  • $ 000
  • Save $ 49908



MSE PRO™ Dimiracetam, ≥98.0% Purity

MSE PRO™ Dimiracetam is a nootropic drug belonging to the racetam family of compounds. It is a rigid analog of piracetam and was initially developed as a potential treatment for HIV-induced neuropathic pain. It modulates the release of neurotransmitters like glutamate, noradrenaline, and acetylcholine from brain and spinal cord synaptosomes by interacting with presynaptic release-regulating receptors, particularly ionotropic glutamate receptors.

MSE Supplies offers various N-heterocyclic drug small molecules and other chemical reagents. Please contact us for bulk orders.

Technical Specifications:

CAS No. 126100-97-8
Chemical name Dimiracetam
Synonym(s)
  • Dihydro-1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione
  • 1H-Pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione
Molecular formula C6H8N2O2
Pack size

5 mg (CM1368)

Molecular weight 140.14 g/mol
Purity ≥98.0% (NMR)
Appearance Light yellow to yellow solid
Storage  2-8°C, protect from light


References:

[1] Farina, C., Gagliardi, S., Ghelardini, C., Martinelli, M., Norcini, M., Parini, C., ... & Ronzoni, S. (2008). Synthesis and biological evaluation of novel dimiracetam derivatives useful for the treatment of neuropathic pain. Bioorganic & medicinal chemistry16(6), 3224-3232.

[2] Fariello, R. G., Ghelardini, C., Mannelli, L. D. C., Bonanno, G., Pittaluga, A., Milanese, M., ... & Farina, C. (2014). Broad spectrum and prolonged efficacy of dimiracetam in models of neuropathic pain. Neuropharmacology81, 85-94.